The MVA-CoV2-S vaccine developed at the CNB-CSIC is highly immunogenic and completely effective against SARS-CoV-2/COVID-19: future and opportunities
Journal: Anales de la Real Academia Nacional de Farmacia
Year: 2022

The appearance of a new emerging virus at the end of 2019, later identified as SARS-CoV-2, which rapidly spread to the human population causing the COVID-19 pandemic (with more than 639 million people infected and more than 6.6 million deaths by November 2022), was a great challenge for science, with serious consequences for the human health system and global economy. In record time, different types of vaccines were produced that demonstrated their safety and efficacy in clinical trials and whos